Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
John V Heymach, Gerrina Ruiter, Myung-Ju Ahn...
https://pubmed.ncbi.nlm.nih.gov/40293180/Actively Recruiting
Led by Boehringer Ingelheim · Updated on 2026-10-28
554
Participants Needed
85
Research Sites
78 weeks
Total Duration
Researchers are studying zongertinib, a medicine given as tablets once or twice daily, in adults with advanced cancers that have changes in the HER2 gene, including non-small cell lung cancer with specific HER2 mutations. The study has two parts the first aims to find the highest safe dose of zongertinib, and the second tests whether this dose can shrink tumors. This is a phase 1, open-label trial with participants who have not responded to previous treatments. In the first part, patients receive increasing doses of zongertinib alone to determine the maximum tolerated dose. Once this dose is established, it is used in the second part to evaluate tumor response. Participants continue taking zongertinib as long as they tolerate it and benefit. The study includes several cohorts, some based in the USA, Japan, and China. During the study, doctors regularly check patients health, monitor tumors using criteria like RECIST 1.1 and RANO-BM for brain metastases, and record any side effects possibly caused by zongertinib. The study measures outcomes such as maximum tolerated dose, dose-limiting toxicities, tumor response, disease control, progression-free survival, quality of life, and overall survival over up to 12 months. Participants remain in the trial as long as treatment is beneficial and tolerable.
CONDITIONS
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
B
Boehringer Ingelheim
A
Additional US locations available on demand. Please contact for options.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Boehringer Ingelheim
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Zongertinib (investigational arm) | Platinum‑based chemotherapy ± immunotherapy (current care) |
|---|---|---|
| What it is | An investigational oral tyrosine kinase inhibitor targeting HER2 aberrations, administered in sequential dose‑escalation and expansion cohorts in a single‑group design | Conventional first‑line treatment approach for advanced HER2‑mutant NSCLC historically relies on platinum‑based chemotherapy with or without immunotherapy |
| Role in trial | Only investigational treatment received by participants across all cohorts | Represents what patients would otherwise receive outside the trial |
| Primary use | Evaluated as a targeted treatment aimed at HER2‑altered advanced solid tumors, including NSCLC | Used as standard initial systemic therapy in advanced NSCLC without specific molecular targeting |
| How it is given or performed | Oral administration in sequential dose groups (escalation then expansion cohorts) | Typically administered intravenously as platinum‑based chemotherapy, sometimes combined with immune checkpoint inhibitor |
| Evidence status | Currently under investigation; clinical trial effect size and safety data pending | Historical use with limited effectiveness in HER2‑mutant NSCLC prior to targeted treatments |
| Important limitations | Single‑group sequential study without randomized comparator, results not yet established | Not molecularly targeted; efficacy in HER2‑mutant NSCLC was modest |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened to confirm eligibility based on their cancer diagnosis, health status, and lab results.
1 visit (in-person)
Duration - Up to 21-day cycles until maximum tolerated dose is determined
Participants receive increasing doses of zongertinib taken as tablets once or twice daily to find the highest dose they can tolerate.
Regular visits during each 21-day cycle
Duration - Up to 12 months or as long as treatment is beneficial and tolerated
After the safe dose is found, participants receive zongertinib at this dose to evaluate its effect on tumor shrinkage and disease control.
Regular monitoring visits throughout treatment
Duration - Up to 12 months of outcome measurement
Doctors monitor participants' health, check tumor response, and record any side effects during and after treatment.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Have more questions? Get in touch with our team for quick support
John V Heymach, Gerrina Ruiter, Myung-Ju Ahn...
https://pubmed.ncbi.nlm.nih.gov/40293180/John V Heymach, Noboru Yamamoto, Nicolas Girard...
https://pubmed.ncbi.nlm.nih.gov/41985129/John Heymach, Frans Opdam, Minal Barve...
https://pubmed.ncbi.nlm.nih.gov/36528522/John V Heymach, Frans Opdam, Minal Barve...
https://pubmed.ncbi.nlm.nih.gov/40030100/Boehringer Ingelheim
Lead Sponsor